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A previous study showed a portion of HIV-1 plasma virus was lysed by the addition of exogenous human AB1 seronegative
complement. The current study was performed to determine whether infectious plasma virus was inactivated by complement.
Incubation of plasma virus with AB1-seronegative serum resulted in substantial decreases in infectious titers, demonstrating
that infectious plasma virus is susceptible to complement-mediated inactivation. Although complement also induced some
lysis of plasma virus samples, virus was neutralized to a significantly higher degree, suggesting neutralization did not occur
solely by lysis. Additionally, C5-deficient complement substantially neutralized virus, indicating coating of virus by early
complement components was an important mechanism of neutralization. A portion of some freshly isolated plasma virus
samples bound to complement receptor 2 in the absence of exogenous complement, indicating that early complement
components bound virus in vivo. Furthermore, plasma virus samples that had less C3 deposited on their surface in vivo had
higher infectious titers than samples with a larger fraction with surface C3. These findings suggest that complement can
neutralize HIV-1 plasma virus in vivo by coating with complement proteins. This is the first study to provide evidence that
coating by complement leads to functional inactivation of a virus in vivo. © 1998 Academic Press
INTRODUCTION
Although it is generally accepted that immunity to HIV
helps control virus replication in vivo, an important re-
maining question is the contribution of humoral immunity
to this control. Some studies suggest that humoral mech-
anisms can play an important role. For example, certain
antibody preparations can partially or fully protect chim-
panzees or hu-PBL-SCID mice from HIV challenge, and
passive administration of antibody to HIV-infected per-
sons reduced p24 levels and CD4 counts in some stud-
ies (Gauduin et al., 1997; reviewed in Mascola et al.,
1997). In contrast, the decrease in viremia that occurs
during development of immunity after primary HIV infec-
tion appears to coincide with development of virus-spe-
cific CTL but not with neutralizing antibody (Koup et al.,
1994; Moore et al., 1994). Also, most primary isolates of
HIV-1 are resistant to neutralization with patient sera
(Moore and Ho, 1995).
In most persons infected with HIV type 1 (HIV-1), virus
is present in blood (plasma virus) at levels that can reach
up to several million RNA copies/ml. The number of RNA
copies detected in plasma exceeds the titers of cultur-
able infectious virus by several orders of magnitude
(Coombs et al., 1993; Dewart et al., 1994; Piatak et al.,
1993a,b). However, there can be a wide variation be-
tween individuals in the ratio of infectious virus to total
virus. For example, in one study, although 12 patients had
RNA equivalents of ;1 3 105/ml in plasma, the infec-
tious titer for these patients ranged from 0 to 100 (Dewar
et al., 1994). In another study, the plasma infectious titer
varied by as much as 2 logs in individuals over a time
period when there was no significant change in the RNA
levels for the same plasma samples (Coombs et al.,
1993). There have been many reasons proposed for the
differences in the ratio of infectious plasma virus to RNA,
including inactivation of the virus by neutralizing anti-
body, differences in rates of viral shedding of gp120, and
changes in the amount of defective virus particles (Li et
al., 1991; McKeating et al., 1991; Robert-Guroff et al.,
1985). However, the mechanisms for the variation in this
ratio have not been conclusively determined. Investiga-
tion of factors that contribute to inactivation of plasma
virus is likely to yield important information about the
contribution of humoral immunity to control of HIV-1 rep-
lication. However, few studies have directly studied the
interaction of plasma virus with humoral factors.
One possible mechanism to explain the differences
observed between the levels of RNA and infectious viral
titers in plasma may be that in some individuals, virus
becomes coated with antibody and complement and
thus is noninfectious because it is prevented from bind-
ing to CD41 cells. This mechanism of neutralization
(coating with antibody, complement, or both) has been
described in vitro for other viruses, including influenza,
Epstein–Barr, and Newcastle disease virus (reviewed in
Cooper and Nemerow, 1986). The deposition of antibody
and complement on the surface of these viruses inter-
feres with attachment to infectable cells (Cooper and
Nemerow, 1986). There is some in vivo evidence that this1 To whom reprint requests should be addressed.
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type of immune mechanism may be playing a role in the
neutralization of HIV. For example, a longitudinal study
(Piatak et al., 1993b) followed several patients beginning
at the time of symptomatic acute HIV infection. The RNA
molecules in plasma for one patient remained at ;2 3
105/ml, whereas plasma virus cultures declined from
1000 infectious units/ml 17 days after the onset of symp-
toms to no detectable infectious virus 8 days later.
Results from another study (Sullivan et al., 1996) also
suggest that a portion of plasma virus had antibody
bound to its surface. Thus, a portion of isolated plasma
virus activated complement, resulting in lysis of virions.
The antibody dependence of lysis was suggested by
both a requirement for complement component C2 and
binding of a fraction of the virus to protein A. This study
suggested a possible in vivo sequence of events in
which plasma virus was produced and a portion subse-
quently interacted with circulating antibody. Virus-bound
antibody then began to activate complement, resulting in
lysis of a fraction of virus. Obtaining blood in EDTA
anticoagulant halted the ongoing complement activation,
which resumed on the addition of fresh complement to
the isolated plasma virus, resulting in the observed in
vitro lysis.
Although the above study (Sullivan et al., 1996) showed
that 14–86% of plasma virus isolates were lysed by com-
plement, other studies have shown that ,0.1% of virus
particles in blood are infectious (Piatak et al., 1993a,b;
Wei et al., 1995). Thus, it was possible that lysis of
plasma virus did not affect infectious virus; in fact, it is
reasonable to predict that virus that can be cultured from
plasma would likely not have antibody bound to its sur-
face.
The goal of this study therefore was to determine
whether isolated infectious plasma virus could be inac-
tivated by human complement. We found that both com-
plement and C5-deficient complement, which can poten-
tially coat virus with complement components but not
cause lysis, inactivated 55–96% of infectious plasma
virus. Additionally, C3 breakdown products were ob-
served on a portion of plasma virus before exposure to
complement in vitro, suggesting that complement was
coating a portion of virus in vivo. Virus samples that had
a smaller fraction of complement-coated plasma virus
had higher levels of infectious virus. These findings sug-
gest that complement activation occurs in vivo and neu-
tralizes a portion of infectious HIV by coating the virus
with antibody and complement proteins.
RESULTS
Effect of complement on plasma virus
infectious titers
Experiments to determine whether complement influ-
enced infectious plasma virus were similar to those of a
previous study (Sullivan et al., 1996). Blood obtained from
infected individuals was placed in EDTA, which inacti-
vates complement. Virus was then separated from EDTA
and other plasma proteins by ultracentrifugation through
sucrose and resuspended in either active complement or
HI complement from an AB1-seronegative donor. First,
however, because previous studies have shown that
antibodies that can bind to gp120 via superantigen-like
interactions can be present in the serum of some HIV-
seronegative persons (Berberian et al., 1993), two types
of experiments were performed to determine whether
these antibodies or HIV-cross-reactive antibodies were
present in the AB1 complement source. Free virus
(HIVMN) was incubated with the AB
1 complement source
at a 1:2 final dilution. This treatment did not cause lysis
of virus as determined by the lack of increase in the
amount of free p24 detected in the virus preparation
compared with HI complement treatment (Fig. 1A). In
contrast, preincubation of HIVMN with antibody pooled
from seropositive donors and subsequent incubation
with the AB1 complement source resulted in substantial
virus lysis (69% release of p24) (Fig. 1A), indicating that
the complement source did not contain antibodies that
induced complement-mediated lysis of virions but that it
had potent complement lytic activity when HIV-specific
antibodies were present.
The AB1 complement source also was tested for its
ability to induce C3 deposition on HIV-infected cells
because this is a more sensitive test for HIV-specific
complement-activating antibodies (Spear et al., 1993).
Uninfected and infected H9 T cells were incubated with
complement (1:3 final dilution), and the amount of C3
deposited on cells was measured by flow cytometry. The
AB1 complement source did not induce C3 deposition on
HIV-infected cells compared with uninfected cells (Fig.
1B). However, in the presence of the antibody pool from
seropositive donors, the AB1 complement source in-
duced substantial C3 deposition on infected cells (Fig.
1B. In contrast, the combination of pooled antibody and
complement did not induce C3 deposition on uninfected
cells. Serum complement from a person genetically de-
ficient in production of C5 (C5D) reacted similarly with
infected and uninfected cells in the absence of antibody
(Fig. 1B). These results indicate that the AB1 and the
C5D complement sources did not contain detectable
HIV-cross-reactive complement-activating antibody.
The AB1 complement source was next incubated with
plasma virus isolated from three HIV-infected individuals.
Incubation of plasma virus from all three patients with
complement resulted in decreases in infectious virus
titers compared with incubation with HI complement (Fig.
2). Thus, plasma virus from patient 1 treated with HI
complement had an infectious titer of 625, whereas treat-
ment with complement reduced the titer to 279. This
represents a 55% decrease in infectious titer due to
complement. Decreases of 80 and 94% in infectious
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plasma virus from patients 2 and 3, respectively, were
caused by complement (Fig. 1 and Table 1).
Lysis of total plasma virus due to complement also
was measured and compared with neutralization. The
percentages of virus lysis for patients 1, 2, and 3 were 16,
27, and 47%, respectively (Table 1). Lysis of plasma virus
samples significantly correlated with decreases in infec-
tious viral titers (P 5 0.0495, Mann-Whitney U test).
However, the percentage inactivation of infectious
plasma virus due to complement was significantly higher
than the percentage of lysis (P 5 0.0078, paired t test)
(Table 1). These results suggested that neutralization of
HIV due to incubation with the AB1 serum may not occur
solely by lysis of virions.
C5 dependence of plasma virus neutralization
To determine whether HIV could be neutralized by
complement in the absence of virus lysis, plasma virus
was isolated from three additional blood samples and
incubated with complement from the individual geneti-
cally deficient in C5. Although classic pathway comple-
ment activation can occur in C5D serum, leading to
deposition of components C1, C4, C2, and C3 (Fig. 1B),
this source does not induce any lysis of antibody-coated
sheep erythrocytes (not shown). In parallel, plasma virus
was also incubated with the AB1 complement, HI com-
plement, or HI C5-deficient complement. C5-deficient
complement caused decreases in infectious virus titers
FIG. 2. Complement treatment of plasma virus decreases infectious
virus titers. Plasma virus was isolated from three individuals and
incubated with complement (C) from an AB1-seronegative serum or
heat-inactivated (HIC) complement at a 1:3 final dilution for 1 h at 37°C,
and infectious titers of treated viruses were determined by end point
dilution.
TABLE 1
Complement-Mediated Lysis and Decrease of Infectious
Viral Titer of HIV Plasma Virus
Patient Fold decreasea (%) Lysis 6 SDb
1 2.2 (55%) 16 6 3%
2 5 (80%) 27%
3 15.5 (94%) 47 6 4%
a Fold decrease of infectious viral titer was calculated by dividing the
TCID50 of virus incubated with heat-inactivated complement by the
TCID50 of virus treated with complement (data from Fig. 1). This de-
crease is also shown as a percent decrease.
b Peripheral blood was collected in EDTA anticoagulant, and virus
was isolated by ultracentrifugation. Virus was incubated with normal
human serum as a source of complement for 1 h at 37°C, and the
percentage of virus lysis was determined. Percent inactivation of infec-
tious plasma virus due to complement is significantly higher than the
percent lysis (P50.0078, paired t test).
FIG. 1. Assessment of sera used as sources of complement for
HIV-binding, complement activating antibodies. (A) HIVMN virus pro-
duced in H9 cells was preincubated with either heat-inactivated (HI)
AB1 serum or HI pooled sera from seropositive donors at a 1:10 final
dilution for 1 h at 4°C, ultracentrifuged, and then exposed to comple-
ment (1:2 final dilution). The amount of free p24 detected in the virus
preparations was then determined by ELISA in the absence of deter-
gent and expressed as a percentage 6 SD of the total p24. (B) H9 cells
infected with the HIVMN strain of virus (H9MN) or uninfected H9 cells
(H9) were incubated with complement (1:3 final dilution) for 1 h at 37°C.
As a positive control for complement activation, cells were preincu-
bated with HI pooled sera from seropositive donors (a-HIV Ab) for 1 h
at 4°C and then incubated with complement (1:3). After incubation with
complement, cells were washed and incubated with FITC-labeled
Fab92 goat anti-human C3 antibody, and the amount of C3 deposition
was determined by flow cytometry. Values represent mean linear fluo-
rescence intensity 6 SD.
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similar to those caused by fully functional complement
with virus from all three patients (Fig. 3). Thus, C5-
deficient complement decreased infectious plasma virus
from patients 2.1, 4, and 5 by 80, 96, and 91%, respec-
tively, compared with HI complement and by 80 and 79%
for patients 2.1 and 5 compared with HI C5-deficient
complement. Although the C5-deficient complement was
negative for complement-activating cross-reactive anti-
body (Fig. 1B), it is possible that some other cross-
reactive antibody, such as IgA, was present in this com-
plement source and may have caused the 50% decrease
in infectious titer of plasma virus from patient 5 that was
treated with HI C5-deficient complement. Taken together,
these results indicate that coating by early complement
components can neutralize HIV plasma virus.
Detection of C3 breakdown products on plasma virus
To determine whether any coating of virus by early
complement components occurs in vivo, plasma virus
was isolated from 11 patients and tested for the pres-
ence of C3 complement breakdown products on the
virus surface by binding to complement receptor 2
(CR2) on MT2 cells. Plasma virus was incubated with
MT2 cells alone or MT2 cells preincubated with anti-
CR2 antibody (OKB7), and the percentage bound virus
was determined. There were large differences in bind-
ing of virus to CR2 among virus samples, with virus
from 7 of 11 samples bound with .2% specific binding
to CR2 (median specific binding, 6%; range, 0–40%),
indicating that some C3 (likely in the form of C3dg and
C3d) was bound to a fraction of some plasma virus
samples in vivo (Fig. 4). It is possible that the large
differences in binding reflect differences between in-
dividuals in humoral immune responses against
plasma virus. This finding suggests that complement
FIG. 3. The effect of C5-deficient (C5D) complement treatment of plasma virus on infectious viral titer. Plasma virus was incubated with complement,
heat-inactivated complement, C5D complement, or heat-inactivated C5D complement for 1 h at 37°C, and infectivity was determined by endpoint
dilution. The number above each bar represents the percentage decreases in infectious virus titer compared with heat-inactivated complement.
Patient sample number 2.1 was from the same individual as patient sample number 2 but was obtained 5 months later.
FIG. 4. Binding of plasma virus to CR2 on cells. Plasma virus was
incubated with MT2 cells or MT2 cells preincubated with blocking
anti-CR2 antibody (OKB7) for 1 h at 4°C, and percentage specific
binding 6 SD of virus to CR2 was determined by subtracting the
background amount of virus bound to the OKB7-blocked MT2 cells.
Background binding to OKB7-blocked MT2 cells averaged 7.2% of the
total amount of p24 added to the MT2 cells.
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may neutralize virus in vivo by coating virions with
early complement components.
To determine whether there was a relationship be-
tween infectious plasma virus and complement break-
down products on the surface of plasma virus, the infec-
tious titer (TCID50) of plasma virus isolated from six
individuals was determined and compared with the per-
centage of virus that had detectable complement break-
down products on the viral surface. A significant inverse
relationship between infectious titer and binding to CR2
was observed, with culture-negative plasma virus sam-
ples binding an average of 14.9% to CR2 and culture-
positive plasma virus samples binding an average of
only 0.5% (Fig. 5) (P 5 0.0463, Mann-Whitney U test).
These data show that plasma virus samples that have
higher amounts of virions that have bound C3 are less
infectious, suggesting that neutralization of virions by
coating with complement may be occurring in vivo.
DISCUSSION
This study showed that a portion of isolated HIV-1
plasma virus was neutralized by incubation with comple-
ment from an AB1-seronegative serum donor. The neu-
tralization effect occurred in #1 h, and in all experiments,
.50% of infectious virus was neutralized. However, it
should be noted that not all plasma virus was neutralized
after incubation with the AB1 serum. Thus, a portion of
plasma virus was resistant to the neutralizing effect.
Several observations indicate that complement was
the active neutralizing factor in the AB1 serum source.
First, heat inactivation at 56°C for 30 min destroyed
neutralizing activity. Second, neutralization was signifi-
cantly correlated with release of p24 from virus after
incubation with the AB1 serum. Because release of p24
from virus required disruption of the virus membrane and
because heat inactivation also prevents plasma virus
lysis (Sullivan et al., 1996), it is likely that complement
was responsible for the observed lysis. Other data indi-
cate that complement was the sole neutralizing factor
contributed by the AB1 serum source. Thus, incubation
of the complement source with an HIV-infected cell line
or free virus from a cell line did not result in C3 deposi-
tion or lysis, respectively (Fig. 1). Also, previously pub-
lished studies show that seronegative serum, when in-
cubated with HIV in the absence of anti-HIV antibody,
does not mediate neutralization (Montefiori et al., 1990;
Spear et al., 1992, 1990b). Thus, it is likely that comple-
ment activation on plasma virus was mediated by a
complement-activating property of the isolated virus it-
self rather than by cross-reactive antibody contributed by
the AB1 serum.
Although the current study does not address the iden-
tity of the complement-activating property associated
with plasma virus, a previous study showed that virus
lysis was dependent on C2 and that a portion of isolated
plasma virus bound to protein A, strongly suggesting that
antibody was bound to a fraction of plasma virus. This
antibody may be specific anti-HIV antibody, or it could be
a naturally occurring antibody similar to that described
by Berberian et al. (1993), who have shown that antibod-
ies that are predominantly in the VH31 family of immu-
noglobulins can bind to gp120 via superantigen-like in-
teractions. Levels of these VH31 immunoglobulins can
increase during infection (Berberian et al., 1994); thus, it
is possible that these antibodies bind to plasma virus in
vivo, coisolate with the virus, and are responsible for the
activation of complement in our study. However, we can-
not rule out the possibility that some complement acti-
vation by plasma virus could occur by other mechanisms
such as direct binding of the transmembrane gp41 to
C1q, activating the classic pathway (Ebenbichler et al.,
1991; Stoiber et al., 1995, 1994), or binding of MBP to
carbohydrate side chains of gp120, which could also
activate classic pathway complement components sub-
sequent to C1 (Ezekowitz et al., 1989; Haurum et al.,
1993). In contrast, other studies have shown that intact
HIV or HIV-infected cells activate complement only in the
presence of specific antiviral antibodies (Spear et al.,
1990a,b; Gregersen et al., 1990; June et al., 1991; Robin-
son et al., 1989; Robinson et al., 1988). Several studies
have shown that the classic complement pathway break-
down product C4d is elevated in HIV-infected persons,
whereas alternative pathway breakdown product Bb is
not (Saarloos et al., 1995; Senaldi et al., 1990), also
supporting the possibility that antibody or other classic
pathway activators mediate complement activation on
plasma virus in vivo. Although we favor the interpretation
that some antibody is present on the virus that induces
complement activation, leading to neutralization, this
FIG. 5. The relationship between infectious plasma virus and com-
plement breakdown products on the surface of plasma virus. Plasma
virus was isolated from six individuals, and the percentage of plasma
virus bound specifically to CR21 cells (see Fig. 4 legend) and the
infectious titer were determined for each sample. The number above
each bar represents the TCID50 of the isolated plasma virus sample.
The absolute CD41 counts in the blood of each of the patients were
(from left to right) 76, 2, 0, 0, 0, and 22.
177COMPLEMENT INACTIVATES HIV-1 PLASMA VIRUS
would imply that the antibody is either against a non-
neutralizing epitope or present at too low a concentration
on the plasma virus to neutralize alone.
Although lysis of plasma virus samples significantly
correlated with decreases in infectious viral titers, the
percentage inactivation of infectious plasma virus due to
complement was significantly higher than the percent-
age of lysis. There are two possibilities that could explain
the higher effect on infectious virus. First, infectious virus
may be a different subpopulation than the majority of the
plasma virus and may have a more effective immune
response directed to it. Alternatively, neutralization of
HIV-1 may be a more efficient process than lysis. Previ-
ous studies show that complement inactivates some
viruses by coating virions with complement components,
as well as by lysis. The nonlytic neutralizing mechanism
has been observed in vitro with herpes simplex type 1,
Epstein–Barr, influenza, Newcastle disease, and vac-
cinia viruses (Cooper and Nemerow, 1983, 1986; Sissons
and Oldstone, 1980). In those systems, deposition of C1,
C2, C4, and C3 (nonlytic components) effectively neutral-
ized the virus. If HIV plasma virus was coated in a similar
fashion, the portion that was not lysed might be sterically
hindered from interacting with receptors and thus result
in a decrease in infectious titer. We observed that C5-
deficient complement, which can potentially coat virus
with complement components but not cause lysis, also
inactivated up to 96% of infectious plasma virus. This
indicated that inactivation of HIV by complement due to
coating of the virus was an important mechanism of
neutralization.
This study also provided evidence that complement
breakdown products were present on the surface of a
fraction of plasma virus. These findings suggest that
complement activation occurs in vivo and results in the
deposition of early complement components on virus.
Moreover, plasma virus samples that had a smaller frac-
tion with C3 deposited on their surface were more infec-
tious than plasma virus samples that had a larger frac-
tion with C3 deposited on their surface, suggesting that
activation of complement by plasma virus in vivo neutral-
ized infectious HIV by coating the virus with complement
proteins. We have also attempted Western blotting of
purified plasma virus to more directly demonstrate C3
deposition on virus, but there were several technical
difficulties, including the lower sensitivity of Western
blotting than of the p24 ELISA used in the capture assay.
The results of this study are potentially significant
because they suggest that the process of neutralization
by coating with complement components may be occur-
ring in vivo. Thus, if patients had no complement, the
infectious titers of plasma virus could be much higher.
This implies that some of the isolated plasma virus is
fully functional, infectious virus, except that it has been
coated with complement. Interestingly, the results of this
study also suggest that the ratio of infectious virus to
total virus may be different among individuals due in part
to the differing amounts of antibody and complement
coating virus. Recent studies estimate that ;1 3 1010
virions are produced and cleared from the circulation
every day (Perelson et al., 1996). Some clearance may
occur by direct interaction with antibody and comple-
ment, resulting in complement-mediated lysis or coating
and subsequent uptake by phagocytic cells. However,
the current study suggests that neutralization by comple-
ment may precede clearance. Interestingly, this mode of
neutralization may not be observed by measuring
changes in RNA levels, as has been recently described
(Wei et al., 1995; Perelson et al., 1996), unless coating of
virus by complement leads to phagocytosis.
A recent study presented evidence that host-cell-de-
rived CD59, which inhibits the lytic phase of complement
activation but not deposition of early complement com-
ponents, is present on the surface of plasma virus (Sul-
livan et al., 1996). It is possible that this could partially
account for the observation that virus appeared to be
neutralized by coating more efficiently than it was lysed
by complement.
In conclusion, this study suggests that antibody and
complement play an important role in the control of virus
replication in vivo by inactivating infectious virus. This
study provides evidence that this inactivation occurs by
both complement-mediated lysis and coating of the virus
with antibody and complement, although the coating
mechanism may be more important. This is the first study
in any virus system to provide in vivo evidence that
coating by complement of virus particles can lead to
inactivation.
MATERIALS AND METHODS
Complement and antibody
The serum used as a source of complement was
collected from an HIV-seronegative AB1 donor, and C5-
deficient serum was obtained from a patient with a doc-
umented inherited complement deficiency. The classic
pathway (CH50) activity of each complement source was
determined using standard techniques (Mayer et al.,
1978). Aliquots of serum were also heat inactivated at
56°C for 30 min to destroy complement activity. Serum
was obtained from 10 HIV-positive persons (all positive
by Western blot for all major HIV proteins), pooled, and
heat inactivated to be used as a source of anti-HIV
antibody.
HIV infection of H9 cells
The H9 human T cell line was infected with the HIVMN
strain of HIV-1. Uninfected and infected H9 cells were
grown in RPMI 1640 medium (Whittaker Bioproducts,
Walkersville, MD) containing L-glutamine and 25 mM
HEPES supplemented with 10% heat-inactivated fetal bo-
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vine serum (FBS, Whittaker Bioproducts) (culture medi-
um). The cell line was routinely tested and found to be
negative for mycoplasma contamination. To produce vi-
rus supernatants, cells were pelleted by centrifugation,
and the supernatant was filtered (0.45 mm pore size),
aliquoted, and frozen at 270°C.
Antibody treatment of cell-line-derived virus
Virus from H9 cells was incubated with either heat-
inactivated normal human serum (the same serum that
was used as a complement source) or heat-inactivated
pooled anti-HIV antiserum (1:10 final dilution) in a final
volume of 0.5 ml for 1 h at 4°C. The virus/antibody
mixture was diluted to 4 ml with RPMI 1640 medium and
then ultracentrifuged through 1 ml of 20% sucrose in 50
mM Tris–HCl (pH 8.0) at 40,000 rpm for 1 h in an SW 50.1
rotor at 22°C. Isolated virus was resuspended in serum-
free RPMI 1640 medium.
Detection of complement activation on infected and
uninfected H9 cells
Infected or uninfected H9 cells were washed twice
with culture medium and adjusted to 2 3 106 cells/ml.
Cells were pelleted and resuspended in 50 ml of pooled
anti-HIV antibody (1:3 final dilution) and incubated for 1 h
at 4°C. After the antibody incubation, cells were washed
with RPMI 1640 medium and resuspended in 100 ml of
either a 1:3 dilution of complement or heat-inactivated
complement for 1 h at 37°C. Cells were then washed
twice with phosphate-buffered saline (PBS) containing
0.1% sodium azide (PBS-azide) and stained with 50 ml of
FITC-labeled Fab92 goat anti-human C3 (Organon-
Teknika-Cappel, West Chester, PA) diluted 1:200 in PBS-
azide for 30 min at 4°C. After staining, cells were washed
twice with PBS-azide and fixed with 1% paraformalde-
hyde. The green fluorescence of cells stained for C3 was
determined with an Ortho Cytoron flow cytometer (Ortho
Diagnostic Systems, Raritan, NJ ). The mean channel
fluorescence of 5 3 103 cells was measured on a loga-
rithmic scale and converted to linear fluorescence.
Measurement of infectious HIV plasma virus
Peripheral blood mononuclear cells (PBMCs) were
isolated from HIV-seronegative donors and cultured for 3
days in culture medium with 3 mg/ml phytohemagglutinin
(PHA-P; Sigma Chemical, St. Louis, MO) and 25 U/ml
interleukin-2 (obtained through the AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID,
NIH; contributed by Dr. Maurice Gately, Hoffman-La
Roche, Nutley, NJ). Plasma virus was isolated from EDTA
plasma by ultracentrifugation (150,000 3 g for 1 h) over
20% sucrose as previously described (Sullivan et al.,
1996), and 100 pg of p24 antigen was incubated with
complement or heat-inactivated complement (1:3 final
dilution in serum-free RPMI 1640) for 1 h at 37°C. Six
serial fivefold dilutions of each treated virus were then
added to 2 3 106 PHA-stimulated PBMCs in duplicate in
24-well flat-bottom tissue culture plates (Corning Glass-
works, Corning, NY). The cultures were fed with 0.5 3
106 PHA-stimulated PBMCs on day 7, and after 14 days of
culture, supernatants were collected and tested for HIV
p24 antigen by ELISA (Immunotech, Inc., Westbrook,
ME). The 50% tissue culture infective dose (TCID50) was
calculated by the Spearman–Karber formula (Finney,
1964).
Measurement of viral lysis
Isolated plasma virus or cell-line-derived virus was
incubated with complement (1:3 final dilution) or heat-
inactivated complement for 1 h at 37°C. After incubation,
p24 released from the virions due to complement-medi-
ated lysis was measured by ELISA in the absence of
detergent (Immunotech). Portions of isolated virus were
also incubated with RPMI 1640 or 0.1% Triton X-100
(Sigma Chemical) for 1 h to determine the background
release of p24 or total lysis, respectively. Percentage viral
lysis was calculated by the formula [experimental lysis
(no detergent) - culture medium-treated virus (back-
ground)]/[100% lysis (with detergent) - culture medium
treated virus] 3 100.
Detection of complement breakdown products
associated with plasma virus
The human T cell line MT-2 (Montefiori et al., 1988),
which expresses complement receptor 2 (CR21), was
obtained from the AIDS Research and Reference Re-
agent Program (National Institutes of Health, Rockville,
MD; contributed by Dr. Douglas Richman) and grown in
culture medium. One million MT-2 cells were preincu-
bated with 1 mg of anti-CR2 monoclonal antibody in
serum-free medium (OKB7, Ortho Diagnostic Systems) or
serum-free RPMI 1640 medium alone for 1 h at room
temperature. Isolated plasma virus was then added to
the cells and incubated for an additional hour at 4°C.
Cells were washed four times with PBS, 250 ml of PBS
containing 1% Triton X-100 was added to the pelleted
cells, and the amount of bound plasma virus was deter-
mined by p24 ELISA. The percentage recovery of plasma
virus was calculated by dividing the amount of p24 anti-
gen bound to cells by the total amount of p24 antigen
added to the cells. The percentage specific binding to
CR2 was determined by subtracting the percentage of
plasma virus recovered after the MT2 cells were prein-
cubated with OKB7 from the percentage of plasma virus
recovered after preincubation of the MT2 cells with RPMI
1640. For three of the plasma virus samples, MT2 cells
were also preincubated with a mouse isotype-matched
control antibody, as well as with RPMI 1640 medium.
Because no difference in binding to cells due to the two
179COMPLEMENT INACTIVATES HIV-1 PLASMA VIRUS
treatments was observed, all subsequent experiments
used serum-free medium only.
ACKNOWLEDGMENTS
The authors gratefully acknowledge the contributions of Mrs. Donna
Samano, R.N., and Mrs. Sylvia Villicana for their assistance in the
acquisition of peripheral blood samples. We are also grateful to
Dr. Thomas Lint for helpful suggestions.
REFERENCES
Berberian, L., Goodglick, L., Kipps, T. J., and Braun, J. (1993). Immuno-
globulin VH3 gene products: Natural ligands for HIV gp120. Science
261, 1588–1591.
Berberian, L., Shukla, J., Jefferis, R., and Braun, J. (1994). Effects of HIV
infection on VH3 (D12 idiotope) B cells in vivo. J. Acquir. Immune
Defic. Syndr. 7(7), 641–646.
Coombs, R. W., Henrard, D. R., Mehaffey, W. F., Gibson, J., Eggert, E.,
Quinn, T. C., and Phillips, J. (1993). Cell-free plasma human immuno-
deficiency virus type 1 titer assessed by culture and immunocapture-
reverse transcription-polymerase chain reaction. J. Clin. Microbiol.
31(8), 1980–1986.
Cooper, N. R., and Nemerow, G. R. (1983). Complement, viruses, and
virus-infected cells. Springer Semin. Immunopathol. 6(4), 327–347.
Cooper, N. R., and Nemerow, G. R. (1986). Complement-dependent
mechanisms of virus neutralization. In “Immunobiology of the Com-
plement System.” Academic Press, New York.
Dewar, R. L., Highbarger, H. C., Sarmiento, M. D., Todd, J. A., Vasude-
vachari, M. B., Davey, R. T., Jr., Kovacs, J. A., Salzman, N. P., Lane,
H. C., and Urdea, M. S. (1994). Application of branched DNA signal
amplification to monitor human immunodeficiency virus type 1 bur-
den in human plasma. J. Infect. Dis. 170(5), 1172–1179.
Ebenbichler, C. F., Thielens, N. M., Vornhagen, R., Marschang, P.,
Arlaud, G. J., and Dierich, M. P. (1991). Human immunodeficiency
virus type 1 activates the classical pathway of complement by direct
C1 binding through specific sites in the transmembrane glycoprotein
gp41. J. Exp. Med. 174(6), 1417–1424.
Ezekowitz, R. A., Kuhlman, M., Groopman, J. E., and Byrn, R. A. (1989). A
human serum mannose-binding protein inhibits in vitro infection by
the human immunodeficiency virus. J. Exp. Med. 169(1), 185–196.
Finney, D. J. (1964). “Statistical Method in Biological Assay.” 2nd ed.
Griffin, London.
Gaudin, M. C., Parren, P. W., Weir, R., Barbas, C. F., Burton, D. R., and
Koup, R. A. (1997). Passive immunization with a human monoclonal
antibody protects hu-PBL-SCID mice against challenge by primary
isolates of HIV-1. Nat. Med. 3(12), 1389–1393.
Gregersen, J. P., Mehdi, S., Baur, A., and Hilfenhaus, J. (1990). Antibody-
and complement-mediated lysis of HIV-infected cells and inhibition
of viral replication. J. Med. Virol. 30(4), 287–293.
Haurum, J. S., Thiel, S., Jones, I. M., Fischer, P. B., Laursen, S. B., and
Jensenius, J. C. (1993). Complement activation upon binding of man-
nan-binding protein to HIV envelope glycoproteins. AIDS 7(10), 1307–
1313.
June, R. A., Schade, S. Z., Bankowski, M. J., Kuhns, M., McNamara, A.,
Lint, T. F., Landay, A. L., and Spear, G. T. (1991). Complement and
antibody mediate enhancement of HIV infection by increasing virus
binding and provirus formation. AIDS 5(3), 269–274.
Koup, R. A., Safrit, J. T., Cao, Y., Andrews, C. A., McLeod, G., Borkowsky,
W., Farthing, C., and Ho, D. D. (1994). Temporal association of cellular
immune responses with the initial control of viremia in primary
human immunodeficiency virus type 1 syndrome. J. Virol. 68(7), 4650–
4655.
Li, Y., Kappes, J. C., Conway, J. A., Price, R. W., Shaw, G. M., and Hahn,
B. H. (1991). Molecular characterization of human immunodeficiency
virus type 1 cloned directly from uncultured human brain tissue:
Identification of replication-competent and -defective viral genomes.
J. Virol. 65(8), 3973–3985.
Mascola, J. R., Louder, M. K., VanCott, T. C., Sapan, C. V., Lambert, J. S.,
Muenz, L. R., Bunow, B., Birx, D. L., and Robb, M. L. (1997). Potent and
synergistic neutralization of human immunodeficiency virus (HIV)
type 1 primary isolates by hyperimmune anti-HIV immunoglobulin
combined with monoclonal antibodies 2F5 and 2G12. J. Virol. 71(10),
7198–7206.
Mayer, M. M., Hammer, C. H., Michaels, D. W., and Shin, M. L. (1978).
Immunologically mediated membrane damage: The mechanism of
complement action and the similarity of lymphocyte-mediated cytox-
icity. Immunochemistry 15(10–11), 813–831.
McKeating, J. A., McKnight, A., and Moore, J. P. (1991). Differential loss
of envelope glycoprotein gp120 from virions of human immunodefi-
ciency virus type 1 isolates: Effects on infectivity and neutralization.
J. Virol. 65(2), 852–860.
Montefiori, D. C., Robinson, W. E., Jr., Hirsch, V. M., Modliszewski, A.,
Mitchell, W. M., and Johnson, P. R. (1990). Antibody-dependent en-
hancement of simian immunodeficiency virus (SIV) infection in vitro
by plasma from SIV-infected rhesus macaques. J. Virol. 64(1), 113–
119.
Montefiori, D. C., Robinson, W. E., Jr., Schuffman, S. S., and Mitchell,
W. M. (1988). Evaluation of antiviral drugs and neutralizing antibodies
to human immunodeficiency virus by a rapid and sensitive microtiter
infection assay. J. Clin. Microbiol. 26(2), 231–235.
Moore, J. P., Cao, Y., Ho, D. D., and Koup, R. A. (1994). Development of
the anti-gp120 antibody response during seroconversion to human
immunodeficiency virus type 1. J. Virol. 68(8), 5142–5155.
Moore, J. P., and Ho, D. D. (1995). HIV-1 neutralization: The conse-
quences of viral adaptation to growth on transformed T cells. AIDS 9,
Suppl A, S117–S136.
Perelson, A. S., Neumann, A. U., Markowitz, M., Leonard, J. M., and Ho,
D. D. (1996). HIV-1 dynamics in vivo: Virion clearance rate, infected
cell life-span, and viral generation time. Science 271(5255), 1582–
1586.
Piatak, M., Jr., Saag, M. S., Yang, L. C., Clark, S. J., Kappes, J. C., Luk,
K. C., Hahn, B. H., Shaw, G. M., and Lifson, J. D. (1993a). Determina-
tion of plasma viral load in HIV-1 infection by quantitative competitive
polymerase chain reaction. AIDS 7, Suppl 2, S65–S71.
Piatak, M., Jr., Saag, M. S., Yang, L. C., Clark, S. J., Kappes, J. C., Luk,
K. C., Hahn, B. H., Shaw, G. M., and Lifson, J. D. (1993b). High levels
of HIV-1 in plasma during all stages of infection determined by
competitive PCR. Science 259, 1749–1754.
Robert-Guroff, M., Brown, M., and Gallo, R. C. (1985). HTLV-III-neutral-
izing antibodies in patients with AIDS and AIDS-related complex.
Nature 316, 72–74.
Robinson, W. E., Jr., Montefiori, D. C., Gillespie, D. H., and Mitchell,
W. M. (1989). Complement-mediated, antibody-dependent enhance-
ment of HIV-1 infection in vitro is characterized by increased protein
and RNA syntheses and infectious virus release. J. Acquir. Immune
Defic. Syndr. 2(1), 33–42.
Robinson, W. E., Jr., Montefiori, D. C., and Mitchell, W. M. (1988).
Antibody-dependent enhancement of human immunodeficiency virus
type 1 infection. Lancet 1, 790–794.
Saarloos, M. N., Koenig, R. E., and Spear, G. T. (1995). Elevated levels
of iC3b and C4d, but not Bb, complement fragments from plasma of
persons infected with human T cell leukemia virus (HTLV) with
HTLV-I-associated myelopathy/tropical spastic paraparesis. J. Infect.
Dis. 172(4), 1095–1097.
Senaldi, G., Peakman, M., McManus, T., Davies, E. T., Tee, D. E., and
Vergani, D. (1990). Activation of the complement system in human
immunodeficiency virus infection: Relevance of the classical path-
way to pathogenesis and disease severity. J. Infect. Dis. 162(6),
1227–1232.
Sissons, J. G., and Oldstone, M. B. (1980). Antibody-mediated destruc-
tion of virus-infected cells. Adv. Immunol. 29, 209–260.
Spear, G. T., Carlson, J. R., Jennings, M. B., Takefman, D. M., and
180 SULLIVAN, TAKEFMAN, AND SPEAR
Landay, A. L. (1992). Complement-mediated, antibody-dependent
neutralizing titers of sera from asymptomatic and symptomatic HIV-
infected individuals. AIDS 6(9), 1047.
Spear, G. T., Landay, A. L., Sullivan, B. L., Dittel, B., and Lint, T. F. (1990a).
Activation of complement on the surface of cells infected by human
immunodeficiency virus. J. Immunol. 144(4), 1490–1496.
Spear, G. T., Sullivan, B. L., Landay, A. L., and Lint, T. F. (1990b).
Neutralization of human immunodeficiency virus type 1 by comple-
ment occurs by viral lysis. J. Virol. 64(12), 5869–5873.
Spear, G. T., Takefman, D. M., Sullivan, B. L., Landay, A. L., and Zolla-
Pazner, S. (1993). Complement activation by human monoclonal an-
tibodies to human immunodeficiency virus. J. Virol. 67(1), 53–59.
Stoiber, H., Ebenbichler, C., Schneider, R., Janatova, J., and Dierich, M. P.
(1995). Interaction of several complement proteins with gp120 and gp41,
the two envelope glycoproteins of HIV-1. AIDS 9(1), 19–26.
Stoiber, H., Thielens, N. M., Ebenbichler, C., Arlaud, G. J., and
Dierich, M. P. (1994). The envelope glycoprotein of HIV-1 gp120
and human complement protein C1q bind to the same peptides
derived from three different regions of gp41, the transmembrane
glycoprotein of HIV-1, and share antigenic homology. Eur. J. Im-
munol. 24(2), 294–300.
Sullivan, B. L., Knopoff, E. J., Saifuddin, M., Takefman, D. M., Saar-
loos, M. N., Sha, B. E., and Spear, G. T. (1996). Susceptibility
of HIV-1 plasma virus to complement-mediated lysis: Evidence
for a role in clearance of virus in vivo. J. Immunol. 157(4), 1791–
1798.
Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A.,
Deutsch, P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B. H.,
and et al. (1995). Viral dynamics in human immunodeficiency virus
type 1 infection. Nature 373(6510), 117–122.
181COMPLEMENT INACTIVATES HIV-1 PLASMA VIRUS
